Atossa Genetics - Endoxifen to start Phase II studies shortly
Atossa Genetics is preparing to start Phase II studies of both its oral and topical endoxifen formulations in Q218. Endoxifen, an estrogen receptor...
174 Views
Atossa Genetics - Seeking to prevent or treat breast cancer
Atossa Genetics reported Phase I data on its topical endoxifen formulation and it is now developing this as a potential treatment for high...
177 Views
Funded into Q417, endoxifen now in Phase I
Atossa raised $4.4m in April 2017 in an equity raise consisting of common shares, Series A convertible preferred shares (SACPS), and warrants. We...
255 Views
Atossa to raise $4.0m in combined class offering
Atossa intends to raise $4.0m (gross proceeds), excluding over-allotments, in an equity offering of Class A and Class B units, consisting of 0.664m...
150 Views
No more insights